A Phase 3 Trial of Antibody hu3F8 and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in High-Risk Neuroblastoma Patients with Primary or Secondary Refractory Osteomedullary Disease

T
Terry Vik, MD

Primary Investigator

Overview

The purpose of this research trial is to find out about the treatment effects of an antibody called humanized 3F8 (hu3F8).

Description

Children and adults diagnosed with high-risk neuroblastoma patients with primary refractory disease or incomplete response to salvage treatment in bone and/or bone marrow will be treated for up to 93 weeks with naxitamab and granulocyte-macrophage colony stimulating factor (GM-CSF). Patients will be followed for up to five years after first dose. Naxitamab, also known as hu3F8 is a humanised monoclonal antibody targeting GD2.

Eligibility

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Neuroblastoma,Osteomedullary Disease,Osteomedullary Disease
  • Age: Between 1 Years - 100 Years
  • Gender: All

Inclusion Criteria
Diagnosis of neuroblastoma (NB)
High-risk neuroblastoma with either primary refractory or secondary refractory osteomedullary disease (persistent neuroblastoma at osteomedullary sites after prior treatment)
Life expectancy ? 6 months
Exclusion Criteria
Any systemic anti-cancer therapy, including chemotherapy or immunotherapy, within 3 weeks before 1st dose of GM-CSF
Evaluable neuroblastoma outside bone and bone marrow
Existing major organ dysfunction > Grade 2, with the exception of hearing loss, hematological status, kidney and liver function
Active life-threatening infection

Additional Information:
Participants will be reimbursed for their participation as needed. Please discuss with study team.

Updated on 09 Mar 2024. Study ID: 1711085080 (PHO-YMABS-201)

Connect with a study center near you

What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center